Services

ITT Labs:

1. Performs enzymatic assays to determine enzyme activity, in an attempt to predict toxicity/response to various chemotherapy drugs, such as measuring DPD enzyme activity to help predict those patients that are at a greater risk of developing severe grade 3-4 toxicity to the chemotherapy drug 5-Fluorouracil or 5-FU based drugs (ie Adrucil, Efudex, Fluoroplex, Xeloda, and Carac)

DPD Enzyme Deficiency Test for 5-Fluorouracil Based Drugs (5-FU) - $400.00

CLICK HERE FOR MORE INFORMATION ABOUT THE DPD ENZYME DEFICIENCY TEST

CLICK HERE TO COMPLETE A TEST REQUEST FORM

2. Performs enzymatic assays, enzyme inhibition studies, or enzyme kinetics for pharmaceutical companies on a per sample basis or using high throughput screening to assist in the preclinical or clinical development of lead compounds and potential drug candidates. ITT Labs is capable of performing assays for enzymes of the purine and pyrimidine metabolic pathways, kinases, and CYP450s, among others, from a variety of sources including blood, normal or tumor tissue, cell lines, or recombinant enzymes. Additionally, ITT Labs is well equipped to perform UV, luminescent, or fluorescent screening and is licensed to use radioactive materials if a radioactive substrate is required to measure activity in the native enzyme.
ITT Labs is CLIA certified to perform enzymatic assays – CLIA # 01D1099109

3. Performs in vitro drug sensitivity assays to determine sensitivity of the tumor to a panel of chemotherapeutic agents to determine which drug has the best potential to show the greatest efficacy, if tumor tissue is available from the patient.

4. Performs genotyping assays to detect sequence variations in the cytochrome p450 enzymes and the enzymes involved in chemotherapy drug metabolism to predict efficacy and/or toxicity.

5. Performs gene expression assays, based on tumor type and suggested treatment, to predict potential efficacy, resistance or toxicity to the prescribed chemotherapy drug.

6. Isolates rare circulating tumor cells in cancer patients as an alternative source of tumor DNA/RNA (without the need for an invasive tumor biopsy).

7. Maintains a database of cancer patients with data from the objectives above; including tumor sensitivity, enzyme activities, and genotype and gene expression of those genes involved in metabolism of chemotherapeutic agents; with patient demographics, response to treatment, toxicity, and disease regression/time to progression, etc.